Literature DB >> 23636538

Optic nerve tortuosity in children with neurofibromatosis type 1.

Joyce Ji1, Joshua Shimony, Feng Gao, Robert C McKinstry, David H Gutmann.   

Abstract

BACKGROUND: Optic nerve tortuosity is often reported in children with neurofibromatosis type 1 (NF1).
OBJECTIVE: To employ quantitative and subjective criteria to assess optic nerve tortuosity in individuals with NF1.
MATERIALS AND METHODS: A retrospective study over a period of 8 years was performed on children with NF1, with and without optic pathway glioma, compared with children without NF1. A tortuosity index was computed for the optic nerve in each child using a high-resolution 3-D T1-weighted magnetization-prepared rapid gradient-echo sequence, which was averaged and compared across groups.
RESULTS: The tortuosity index for subjects with NF1, regardless of an optic pathway glioma, was greater than those without NF1. There was no difference in the tortuosity index between NF1 subjects with optic pathway glioma and NF1 subjects without optic pathway glioma. There was also no correlation between subjective measures of tortuosity and the quantitative scoring (tortuosity index) or between the degree of tortuosity and subject age or gender.
CONCLUSION: Individuals with NF1 have increased optic nerve tortuosity relative to unaffected individuals. Quantitative tortuosity index is a superior measure to subjective assessment in the evaluation of optic nerve tortuosity in children with NF1.

Entities:  

Mesh:

Year:  2013        PMID: 23636538      PMCID: PMC3904184          DOI: 10.1007/s00247-013-2694-1

Source DB:  PubMed          Journal:  Pediatr Radiol        ISSN: 0301-0449


  20 in total

1.  Natural history of cognitive deficits and their relationship to MRI T2-hyperintensities in NF1.

Authors:  S L Hyman; D S Gill; E A Shores; A Steinberg; P Joy; S V Gibikote; K N North
Journal:  Neurology       Date:  2003-04-08       Impact factor: 9.910

2.  Prognostic factors of CNS tumours in Neurofibromatosis 1 (NF1): a retrospective study of 104 patients.

Authors:  Jean-Sébastien Guillamo; Alain Créange; Chantal Kalifa; Jacques Grill; Diana Rodriguez; François Doz; Sébastien Barbarot; Michel Zerah; Marc Sanson; Sylvie Bastuji-Garin; Pierre Wolkenstein
Journal:  Brain       Date:  2003-01       Impact factor: 13.501

3.  Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference.

Authors: 
Journal:  Arch Neurol       Date:  1988-05

4.  Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging.

Authors:  L J Balcer; G T Liu; G Heller; L Bilaniuk; N J Volpe; S L Galetta; P T Molloy; P C Phillips; A J Janss; S Vaughn; M G Maguire
Journal:  Am J Ophthalmol       Date:  2001-04       Impact factor: 5.258

5.  Quantitative morphology of the corpus callosum in children with neurofibromatosis and attention-deficit hyperactivity disorder.

Authors:  A E Kayl; B D Moore; J M Slopis; E F Jackson; N E Leeds
Journal:  J Child Neurol       Date:  2000-02       Impact factor: 1.987

6.  Brain volume in children with neurofibromatosis type 1: relation to neuropsychological status.

Authors:  B D Moore; J M Slopis; E F Jackson; A E De Winter; N E Leeds
Journal:  Neurology       Date:  2000-02-22       Impact factor: 9.910

7.  Neurofibromatosis type 1: magnetic resonance imaging findings.

Authors:  F J DiMario; G Ramsby; R Greenstein; S Langshur; B Dunham
Journal:  J Child Neurol       Date:  1993-01       Impact factor: 1.987

8.  Natural history of optic pathway tumors in children with neurofibromatosis type 1: a longitudinal study.

Authors:  R Listernick; J Charrow; M Greenwald; M Mets
Journal:  J Pediatr       Date:  1994-07       Impact factor: 4.406

9.  Optic gliomas in children with neurofibromatosis type 1.

Authors:  R Listernick; J Charrow; M J Greenwald; N B Esterly
Journal:  J Pediatr       Date:  1989-05       Impact factor: 4.406

10.  Optic pathway gliomas in neurofibromatosis type 1: the effect of presenting symptoms on outcome.

Authors:  Allison King; Robert Listernick; Joel Charrow; Linda Piersall; David H Gutmann
Journal:  Am J Med Genet A       Date:  2003-10-01       Impact factor: 2.802

View more
  5 in total

Review 1.  Optic Pathway Gliomas in Neurofibromatosis Type 1: An Update: Surveillance, Treatment Indications, and Biomarkers of Vision.

Authors:  Peter M K de Blank; Michael J Fisher; Grant T Liu; David H Gutmann; Robert Listernick; Rosalie E Ferner; Robert A Avery
Journal:  J Neuroophthalmol       Date:  2017-09       Impact factor: 3.042

2.  The cyclic AMP pathway is a sex-specific modifier of glioma risk in type I neurofibromatosis patients.

Authors:  Nicole M Warrington; Tao Sun; Jingqin Luo; Robert C McKinstry; Patricia C Parkin; Sara Ganzhorn; Debra Spoljaric; Anne C Albers; Amanda Merkelson; Douglas R Stewart; David A Stevenson; David Viskochil; Todd E Druley; Jason T Forys; Karlyne M Reilly; Michael J Fisher; Uri Tabori; Jeffrey C Allen; Joshua D Schiffman; David H Gutmann; Joshua B Rubin
Journal:  Cancer Res       Date:  2014-11-07       Impact factor: 12.701

3.  Genomic architecture of fetal central nervous system anomalies using whole-genome sequencing.

Authors:  Ying Yang; Sheng Zhao; Guoqiang Sun; Fang Chen; Tongda Zhang; Jieping Song; Wenzhong Yang; Lin Wang; Nianji Zhan; Xiaohong Yang; Xia Zhu; Bin Rao; Zhenzhen Yin; Jing Zhou; Haisheng Yan; Yushan Huang; Jingyu Ye; Hui Huang; Chen Cheng; Shida Zhu; Jian Guo; Xun Xu; Xinlin Chen
Journal:  NPJ Genom Med       Date:  2022-05-13       Impact factor: 6.083

4.  Serial MRIs provide novel insight into natural history of optic pathway gliomas in patients with neurofibromatosis 1.

Authors:  Laura Sellmer; Said Farschtschi; Marco Marangoni; Manraj K S Heran; Patricia Birch; Ralph Wenzel; Victor-Felix Mautner; Jan M Friedman
Journal:  Orphanet J Rare Dis       Date:  2018-04-23       Impact factor: 4.123

5.  Asthma reduces glioma formation by T cell decorin-mediated inhibition of microglia.

Authors:  Jit Chatterjee; Shilpa Sanapala; Olivia Cobb; Alice Bewley; Andrea K Goldstein; Elizabeth Cordell; Xia Ge; Joel R Garbow; Michael J Holtzman; David H Gutmann
Journal:  Nat Commun       Date:  2021-12-08       Impact factor: 14.919

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.